MENU
中文
R&ampD Innovation

R&D Innovation

R&D INNOVATION

Home>R&D Innovation>R&D Achievements 
R&D Achievements

In a groundbreaking achievement, Inno Medicine has developed an innovative targeted therapy of atherosclerosis, resulting from a successful technology transfer collaboration with Beijing Anzhen Hospital. This remarkable advancement enables precise and effective treatment of atherosclerosis by employing a unique active targeting delivery system, ensuring the drug reaches the intended site to deliver its therapeutic benefits. YN001 has received IND approval from the US FDA and China NMPA, becoming the world's first cardiovascular targeted drug to enter clinical trials, is expected to become the first cardiovascular drug in history to obtain FDA approval through Accelerated Approval, and become a disruptive treatment method in this field. The project has been granted by the National 14th Five-Year Key Research and Development Program of China, and has obtained funding support from multiple research projects from the National Natural Science Foundation of China and the Beijing Natural Science Foundation.

Huge Unmet Clinical Need for AS,
Lack of Substantial and Effective Combination Protocol of Diagnosis and Treatment up to Now
Atherosclerosis
Clinical manifestations include

Atherosclerosis

Atherosclerosis (AS) refers to the formation of atherosclerotic plaques in arteries which cause luminal stenosis. Once the plaque ruptures and forms thrombus, ischemic necrosis of the corresponding organs will occur, usually leading to irreversible damage

Clinical manifestations include

coronary atherosclerosis disease (coronary heart disease), cerebral atherosclerosis disease, peripheral atherosclerosis disease

No Substantial and Clinical Effective Combination Protocol of Diagnosis and Treatment for AS can be Achieved with Current Methods<br>Huge Unmet Clinical Need and Market Space with Less Competition

No Substantial and Clinical Effective Combination Protocol of Diagnosis and Treatment for AS can be Achieved with Current Methods
Huge Unmet Clinical Need and Market Space with Less Competition

World's First Combination Protocol of Targeted Diagnosis and
Treatment to Reverse AS Inflammatory Plaques is Under Study
Combination Protocol of Targeted Diagnosis and Treatment for Inflammatory Plaque Reversal by INNO

Combination Protocol of Targeted Diagnosis and Treatment for Inflammatory Plaque Reversal by INNO

YN001 Targeted lipid delivery precision therapy

  • Targeted delivery by binding of the target head to the ligand, enrichment to the target site, achieving higher exposure, down-regulation of inflammation-related signaling pathways in macrophages and fibroblasts, and plaque reversal exceeding 50%
  • Comprehensive proprietary patent system protection for receptor + ligand targeted delivery systems
  • Many technical details of the high-end and complex preparation process of nano lipids that are difficult to replicate have also contributed to patent protection, which can fully extend patent protection and reinforce barriers, with high thresholds, difficult to replicate, and long-lasting returns

YN002 New generation lipid contrast agent for accurate diagnosis

  • Non-invasive targeting of vulnerable plaques, precise developing, identification of high-risk patients, early intervention or treatment
  • MRI contrast media nanoparticles can target vulnerable plaque sites
  • Development starts after 2 hours, the signal is strongest at the 6th hour, and then weakens

Beijing Inno Medicine Co., Ltd.

Address: Building 9, Area C, Xishan Creative Park, Haidian District, Beijing

Telephone number: +86 8259 9080

Contact Us:

Copyright © Copyright 2020 Beijing Inno Medicine Co., Ltd. Beijing ICP Preparation No. 2020036980 京ICP备2020036980号

Legal Notice| Privacy Policy